A dose-finding study with a novel water-soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumours in dogs.
作者： Henrik Von Euler , Patricio Rivera , Helena Nyman , Jens Häggström , O Borgå
DOI: 10.1111/J.1476-5829.2011.00314.X
关键词:
摘要: A new formulation of water-soluble paclitaxel (Paccal® Vet) has been developed for canine cancer patients, without the need pre-medication (traditionally required in non-water-soluble formulations). The objective study was to determine a clinically safe and efficacious dose Paccal Vet estimate progression-free overall survival evaluate single-dose pharmacokinetics tumour-bearing dogs. positive risk:benefit ratio established administered at 150 mg m(-2) intravenous (IV) three or more treatment cycles. Preliminary efficacy demonstrated by best response rate (86%), median time (14 days) (131 days). associated with expected adverse events (AE) (e.g. myelosuppression), however majority were transient, silent manageable. This is first clinical report suggesting successful administration being safely used
sci-hub.se 参考文章(34)
R T Bronson, Variation in age at death of dogs of different sexes and breeds. American Journal of Veterinary Research. ,vol. 43, pp. 2057- 2059 ,(1982)
S.E. Rau, L.G. Barber, K.E. Burgess, Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs. Journal of Veterinary Internal Medicine. ,vol. 24, pp. 1452- 1457 ,(2010) , 10.1111/J.1939-1676.2010.0611.X
Nicolas Penel, Amélie Lansiaux, Antoine Adenis, Angiosarcomas and Taxanes Current Treatment Options in Oncology. ,vol. 8, pp. 428- 434 ,(2007) , 10.1007/S11864-007-0042-0
D.F. Merlo, L. Rossi, C. Pellegrino, M. Ceppi, U. Cardellino, C. Capurro, A. Ratto, P.L. Sambucco, V. Sestito, G. Tanara, V. Bocchini, Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. Journal of Veterinary Internal Medicine. ,vol. 22, pp. 976- 984 ,(2008) , 10.1111/J.1939-1676.2008.0133.X
M. Jordan, Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Current Medicinal Chemistry - Anti-cancer Agents. ,vol. 2, pp. 1- 17 ,(2012) , 10.2174/1568011023354290
Daryl S. Sonnichsen, Mary V. Relling, Clinical Pharmacokinetics of Paclitaxel Clinical Pharmacokinectics. ,vol. 27, pp. 256- 269 ,(1994) , 10.2165/00003088-199427040-00002
DM Vail, Henrik Von Euler, AW Rusk, L Barber, C Clifford, R Elmslie, L Fulton, J Hirschberger, M Klein, C London, Marina Martano, EA McNiel, JS Morris, N Northrup, B Phillips, G Polton, G Post, M Rosenberg, D Ruslander, A Sahora, S Siegel, D Thamm, Sara Westberg, J Winter, C Khanna, None, A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs. Journal of Veterinary Internal Medicine. ,vol. 26, pp. 598- 607 ,(2012) , 10.1111/J.1939-1676.2012.00897.X
Kaled M. Alektiar, Vicky Makker, Nadeem R. Abu-Rustum, Robert A. Soslow, Dennis S. Chi, Richard R. Barakat, Carol A. Aghajanian, Concurrent Carboplatin/Paclitaxel and Intravaginal Radiation in Surgical Stage I-II Serous Endometrial Cancer Gynecologic Oncology. ,vol. 112, pp. 142- 145 ,(2009) , 10.1016/J.YGYNO.2008.10.006
Joan L. Walker, Astrid Morrison, Paul DiSilvestro, Vivian E. von Gruenigen, A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study. Gynecologic Oncology. ,vol. 112, pp. 78- 84 ,(2009) , 10.1016/J.YGYNO.2008.09.035
V Alberola, R Rosell, JL Gonzalez-Larriba, F Molina, F Ayala, J Garcia-Conde, D Benito, JM Perez, Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer Annals of Oncology. ,vol. 6, pp. 49- 52 ,(1995) , 10.1093/ANNONC/6.SUPPL_3.S49